{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-056469","form_type":"8-K","ticker":"BGMS","cik":"0001130166","company_name":"Bio Green Med Solution, Inc.","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.388310+00:00","generated_at":"2026-06-02T23:55:27.964320+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cyclacel raises $8M in private placement of common stock and warrants","bullets":["Sold 4,968,945 shares (or pre-funded warrants) plus series A/B warrants at $1.61 per unit; gross proceeds ~$8.0M.","Series A warrants exercisable at $1.36 for 5.5 years; series B warrants for 18 months.","H.C. Wainwright acted as placement agent; fees 7% cash plus 1% management fee and placement agent warrants.","Net proceeds intended for working capital and general corporate purposes."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-056469","json":"https://secwatch.observer/filing/0001104659-24-056469.json","markdown":"https://secwatch.observer/filing/0001104659-24-056469.md","text":"https://secwatch.observer/filing/0001104659-24-056469.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1130166/000110465924056469/0001104659-24-056469-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1130166/000110465924056469/tm2413298d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T23:55:27.964320+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"63bac3254a2cecb55756f290f1026326a24e0938","claim":"Bio Green Med Solution, Inc. entered into Purchase Agreement with an institutional investor valued at approximately $8.0 million (effective 2024-04-30).","evidence_excerpt":"On April 30, 2024, Cyclacel Pharmaceuticals, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreement ”) with an institutional investor (the “ Purchaser ”) for the issuance and sale in a private placement (the “ Private Placement ”) of (i) 145,000 shares of the Company’s common stock","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130166/000110465924056469/0001104659-24-056469-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"an institutional investor"},{"label":"Value","value":"approximately $8.0 million"},{"label":"Effective","value":"2024-04-30"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}